Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease

Burlington, Canada, June 23, 2020  – Boehringer Ingelheim Animal Health Canada Inc. received approval from Health Canada to expand the label claim of NexGard® (afoxolaner) and NexGard Spectra™ (afoxolaner and milbemycin oxime) to include an indication for the reduction of B. burgdorferi infections as a direct result of killing adult I. scapularis vector ticks. B. burgdorferi is the infectious agent which causes Lyme disease in dogs.

NexGard® and NexGard Spectra™ are the first and only parasiticide products in Canada to receive a B. burgdorferi protection label claim. The label claim applies equally to both products because the concentration of afoxolaner is equivalent in both. This now provides the pet owner with heightened ability to prevent Lyme disease in their dog.

“Boehringer Ingelheim’s unwavering commitment to advancing veterinary medicine with a focus on prevention is proudly showcased with this first-ever indication in Canada to reduce the B. burgdorferi infections that cause Lyme disease,” says Mr. Tyron Hansen, Marketing Manager, Pet, Boehringer Ingelheim Animal Health Canada Inc.  “Providing veterinarians and pet owners with reliable and effective products to keep their animals healthy remains our top priority.”

Boehringer Ingelheim Animal Health
Boehringer Ingelheim is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, across the globe, our 10,000 employees are dedicated to enhancing the well-being of both – through science and innovation, as well as with their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

For more information visit: https://www.boehringer-ingelheim.ca/en/animal-health/animal-health-2

Boehringer Ingelheim Canada (Ltd.)
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.ca or in our annual report: http://annualreport.boehringer-ingelheim.com.

References

1. Baker CF, McCall JW, McCall SD et. al. Ability of an oral formulation of afoxolaner to protect dogs from Borrelia burgdorferi infection transmitted by wild Ixodes scapularis ticks. Comp Immunol Microbio Inf Dis. 2016;49:65-69.
2. Boehringer Ingelheim PR&D 0377501